銵?鋆蔭?詨
FIRST-IN-CLASS
DRUG TREATMENTS
Lin BioScience is focused on discovering and developing innovative
drug candidate for the treatment of cancer and eye diseases
ORAL DRUG TREATMENT
for MACULAR DEGENERATION
First-in-Class oral therapeutic candidate for Dry Age-related Macular Degeneration and Stargardt Disease
TARGET THERAPY
with BROAD ONCOLOGY APPLICATIONS
Natural small molecular inhibitor for treatment of broad variety of cancers
NEWS
Sep 16 , 2020 Lin BioScience raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt disease Lin BioScience today announced that it has successfully completed its $30 million Rights Issue. The new funding will enable Lin BioScience to continue to invest in its subsidiary Belite Bio to pursue the Phase 3 clinical trial of its lead RBP4 antagonist LBS-008 for Stargardt disease.
Apr 24 , 2019 Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease U.S. Food and Drug Administration has approved its Investigational New Drug application for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration and Stargardt disease.
Oct 02 , 2018 Belite Bio Initiates Phase 1 Study of LBS-008 in Australia LBS-008 first-in-human phase 1 study is being conducted in healthy volunteers in Australia and is expected to be completed during the 2nd half of 2019.
PIPELINE
Discovery
Preclinical
Phase1
Phase2
008
Dry AMD Stargardt Disease
009
NASH Type 2 Diabetes
007
Acute Leukemia Solid Tumors
002
Glioblastoma Brain Metastasis
Dry AMD
Stargardt Disease
NASH
Type 2 Diabetes
Acute Leukemia
Solid Tumors
Glioblastoma
Brain Metastasis